Mr. Bellemin's tenure concludes as Iovance confronts a series of operational and financial disappointments. The company's first-quarter sales figures for Amtagvi, its recently launched melanoma treatment, significantly underperformed Wall Street's expectations, compelling management to temper its full-year revenue projections. This revised outlook triggered a sharp reaction from analysts, including a downgrade from UBS.